Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Neurology | Musculoskeletal
Clinical Trials: Multiple Sclerosis
A listing of clinical trials currently looking for volunteers to enroll in Multiple Sclerosis studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : Alabama Neurology Associates
A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis
Birmingham : Tanner Center and Foundation for MS
Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire
Birmingham : Research Site Updated
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Cullman : Investigational Site Number 840049 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Cullman : GSK Investigational Site Updated
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
View More »
Cullman : Investigational Site Number 8965 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Cullman : North Central Neurology Associates PC
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Cullman : Teva Investigational Site 10192 Updated
To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS
Alaska
Cordova : Investigational Site Number 840005 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Arizona
Phoenix : Research Site
A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis
Phoenix : St. Joseph’s Hospital and Medical Center
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
Tucson : Research Site
A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis
View More »
Phoenix : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Phoenix : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Phoenix : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Phoenix : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Phoenix : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Phoenix : XenoPort Clinical Site
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Phoenix : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Phoenix : Investigational Site Number 840052 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Phoenix : St. Joseph's Hospital Medical Center
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Scottsdale : Neuromuscular Research Center
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Tempe : Research Site Updated
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Tucson : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Tucson : Northwest NeuroSpecialists, PLLC
A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis
Tucson : Northwest NeuroSpecialists, PLLC
A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis
Tucson : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Tucson : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Tucson : XenoPort Clinical Site
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Tucson : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Arkansas
Little Rock : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
California
Berkeley : Jordan Research and Education Institute
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
Los Angeles : University of Southern California - Keck School of Medicine
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
View More »
Aliso Viejo : Avanir Pharmaceuticals
PRISM Registry: Pseudobulbar Affect Registry Series
Berkeley : XenoPort Clinical Site
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Berkeley : Alta Bates Summit Medical Center
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Fresno : Victoria Walton, MD
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Fresno : Teva Investigational Site 10204 Updated
To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS
Fullerton : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Fullerton : Fullerton Neurology and Headache Center
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Fullteron : GSK Investigational Site Updated
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
Garden Grove : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
La Jolla : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
La Jolla : Coordinated Clinical Research
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Los Angeles : USC MS Comprehensive Care Center
Clinical 15 Months Study Comparing Monthly Pulse ACTH (Acthar Gel) Therapy With Monthly Methylprednisolone (MP, Solumedrol) for Multiple Sclerosis (MS) Patients Who Are on Regular Beta-interferons (Avonex, Betaseron or Rebif)
Los Angeles : University of California Los Angeles
Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
Los Angeles : USC MS Comprehensive Care Center & Research Group
Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities
Los Angeles : USC
Trial of Memantine for Cognitive Impairment in Multiple Sclerosis
Newport Beach : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Newport Beach : Investigational Site Number 840048 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Newport Beach : Research Site Updated
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Newport Beach : Multiple Sclerosis Center of Southern California & Research
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Oakland : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Oceanside : Neurology Center
Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire
Pasadena : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Sacramento : Sutter Institute for Medical Research
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
San Diego : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
San Diego : XenoPort Clinical Site
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
San Francisco : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
San Francisco : University of California, San Francisco
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
San Francisco : University of California San Francisco
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Temecula : Viking Clinical Research Center
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Torrance : Research Site Updated
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Valencia : Sanguine Biosciences
A Biospecimen and Clinical Data Study on Patients With Alzheimer's, Multiple Sclerosis, Parkinson's, and Huntington's, for Drug & Biomarker Discovery
Colorado
Centennial : 1st International Clinical Research Center
Do you have Relapsing Remitting Multiple Sclerosis?
Denver : Research Site
A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis
View More »
Aurora : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Aurora : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Aurora : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Centennial : Research Site
An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
Centennial : Teva Investigational Site 10196 Updated
To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS
Denver : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Denver : XenoPort Clinical Site
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Englewood : Colorado Neurological Institute
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Fort Collins : Investigational Site Number 840036 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Fort Collins : Investigational Site Number 8962 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Fort Collins : Advanced Neurosciences Research
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Ft. Collins : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Ft. Collins : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Ft. Collins : Research Site Updated
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Connecticut
New London : Coastal Connecticut Research, LLC
Are You Currently Being Treated for a Relapsing Form of Multiple Sclerosis?
Pawcatuck : CNS Research of CT, Inc.
A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis.
View More »
Fairfield : GSK Investigational Site Updated
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
Delaware
Newark : Christiana Care Health Services
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Florida
Port Charlotte : Research Site
A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis
Sarasota : Research Site
A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis
St. Petersburg : Research Site
A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis
Tampa : Axiom Clinical Research of Florida
A clinical research study for patients with Primary Progressive Multiple Sclerosis
Tampa : Axiom Clinical Research of Florida
A clinical research study for patients with Relapsing Remitting Multiple Sclerosis
Tampa : Research Site
A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis
View More »
Bradenton : Research Site
An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
Bradenton : Brandenton Neurology, Inc.
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Hollywood : Infinity Clinical Research
Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire
Hollywood : Sunrise Clinical Research, Inc.
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Jacksonville : University of Florida
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Maitland : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Maitland : Investigational Site Number 840012 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Maitland : Investigational Site Number 8920 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Maitland : Neurology Associates, PA
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Maitland : Neurology Associates, PA
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Melbourne : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Miami : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Miami : University of Miami
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Naples : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
North Palm Beach : Laszlo J. Mate, MD
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Orlando : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Orlando : McCare Center Neurology Services
Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire
Ormond Beach : Investigational Site Number 840013 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Ormond Beach : Neurology Associates of Ormond Beach
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Ormond Beach : Neurology Associates of Ormond Beach
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Pompano Beach : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Pompano Beach : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Pompano Beach : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Pompano Beach : Neurological Associates
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Pompano Beach : Neurological Associates
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Port Charlotte : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Port Charlotte : XenoPort Clinical Site
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Port Orange : Progressive Medical Research
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Sarasota : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Sarasota : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Sarasota : XenoPort Clinical Site
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Sarasota : Investigational Site Number 840008 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Sarasota : Roskamp Institute
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Sarasota : Teva Investigational Site 10180 Updated
To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS
South Miami : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
St. Petersburg : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
St. Petersburg : XenoPort Clinical Site
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
St. Petersburg : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
St. Petersburg : Investigational Site Number 840021 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
St. Petersburg : Investigational Site Number 8953 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
St. Petersburg : Suncoast Neuroscience Associates, Inc.
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
St. Petersburg : Suncoast Neuroscience Associates, Inc
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Sunrise : Neurology Clinical Research
Masitinib in Patients With Primary Progressive or Relapse-free Secondary Multiple Sclerosis
Sunrise : GSK Investigational Site Updated
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
Tallahassee : AMO Corporation
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Tampa : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Tampa : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Tampa : XenoPort Clinical Site
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Tampa : Investigational Site Number 840004 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Tampa : Investigational Site Number 840047 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Tampa : University of South Florida
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Tampa : Teva Investigational Site 10190 Updated
To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS
Tampa : Teva Investigational Site 10207 Updated
To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS
Vero Beach : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Vero Beach : Geodyssey Research, LLC
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Vero Beach : MS Center of Vero Beach
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
West Palm Beach : GSK Investigational Site Updated
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
Weston : Cleveland Clinic Florida
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Georgia
Atlanta : NeuroTrials Research
Living with Multiple Sclerosis? Enrolling for a 96-week, non-placebo, comparative trial.
Atlanta : Neurotrials Research, Inc.
Multiple Sclerosis
View More »
Atlanta : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Atlanta : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Atlanta : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Atlanta : Research Site Updated
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Atlanta : GSK Investigational Site Updated
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
Atlanta : Shepard Center
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Decatur : Neurostudies
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Hawaii
Honolulu : Leo Maher, MD
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Illinois
Elk Grove Village : Alexian Brothers Hospital Network
A 6 month, randomized, active comparator, open-label, multi-center study to evaluate patient outcomes, safety and tolerability of Fingolimod (FTY720) 0.5mg/day in patients with relapsing remitting MS who are candidates for MS therapy change from previous disease modifying therapy (EPOC).
Flossmoor : South Suburban Neurology
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
View More »
Barrington : Research Site Updated
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Champaign : Research Site Updated
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Chicago : Investigational Site Number 840034 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Chicago : University of Chicago
Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis
Elk Grove Village : Investigational Site Number 840037 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Evanston : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Flossmoor : South Suburban Neurology
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Lake Barrington : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Lake Barrington : Research Site
An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
Lake Barrington : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Lake Barrington : XenoPort Clinical Site
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Northbrook : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Northbrook : GSK Investigational Site Updated
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
Northbrook : Consultants in Neurology
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Peoria : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Indiana
Indianapolis : Research Site
A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis
View More »
Avon : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Fort Wayne : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Ft. Wayne : Investigational Site Number 840025 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Ft. Wayne : Investigational Site Number 8914 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Indianapolis : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Indianapolis : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Indianapolis : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Indianapolis : XenoPort Clinical Site
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Indianapolis : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Indianapolis : Research Site Updated
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Indianapolis : Investigational Site Number 8940 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Indianapolis : Josephson Wallack Munshower Neurology, P.C.
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Merrillville : Neuroscience Institute
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Iowa
Des Moines : Ruan Neurology Research
Masitinib in Patients With Primary Progressive or Relapse-free Secondary Multiple Sclerosis
Des Moines : Mercy Ruan Neurology Clinic Res Ct.
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Kansas
Lenexa : Research Site
A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis
Lenexa : MidAmerica Neuroscience Institute
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
View More »
Kansas City : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Kansas City : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Kansas City : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Lenexa : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Lenexa : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Lenexa : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Lenexa : XenoPort Clinical Site
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Lenexa : MidAmerica Neuroscience Institute
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Lenexa : Mid America Neuroscience Institute
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Overland Park : Research Site Updated
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Topeka : Precise Clinical Research
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Topeka : Cotton O'Neil Clinical Research Institute
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Kentucky
Lexington : Research Site
A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis
Lexington : Associates in Neurology, P.S.C.
A Phase 3 study of PEGylated Interferon Beta-1a vs Placebo for subjects with Relapsing Remitting Multiple Sclerosis.
Lexington : Associates in Neurology, P.S.C.
A Phase 3 Study to determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex (Interferon-beta-1a) in Patients with Relapsing-Remitting Multiple Sclerosis.
Lexington : Associates in Neurology, P.S.C.
A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to evaluate the efficacy and safety of Ocrelizumab in comparison to Interferon Beta-1a (Rebif) in patients with Relapsing Multiple Sclerosis.
Lexington : Associates in Neurology, P.S.C.
Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral Dalfampridine Extended Release Tablets (5 mg and 10mg twice daily) in Patients with Multiple Sclerosis. Sponsored by: Acorda Therapeutics.
Lexington : Associates in Neurology, P.S.C.
Multicenter, open-labeled, randomized, active comparator research study to evaluate patient outcome, safety and tolerability of an investigational medicine in patients with Relapsing forms of Multiple Sclerosis and who are candidates for MS therapy change from previous disease modifying therapy.
Lexington : Associates in Neurology, P.S.C.
This trial is evaluating the safety and efficacy of an investigational oral medication for the treatment of spasticity in patients with multiple sclerosis (MS).
View More »
Lexington : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Lexington : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Lexington : XenoPort Clinical Site
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Lexington : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Lexington : Associates in Neurology
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Louisville : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Louisville : Investigational Site Number 840033 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Louisville : University of Louisville (recruiting nationwide)
Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms
Louisville : Norton Healthcare, Inc.
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Louisiana
Shreveport : Louisiana State University
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
View More »
Shreveport : Investigational Site Number 8922 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Maryland
Baltimore : University of Maryland
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
View More »
Baltimore : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Baltimore : Investigational Site Number 840028 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Baltimore : University of Maryland
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Baltimore : Johns Hopkins University
Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis
Bethesda : Bethesda Neurology, LLC
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Massachusetts
Bellingham : CNS Research of MA, Inc.
A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis.
Boston : Brigham Women’s Hospital
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
View More »
Boston : Caritas St. Elizabeth's Hospital
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Burlington : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Cambridge : Outcome Sciences, Inc
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials
Milford : Milford Regional Medical Center
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Springfield : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Springfield : Springfield Neurology Associates, LLC
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Worcester : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Worcester : Fallon Clinic at Worcester Medical Center
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Worchester : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Michigan
Bingham Farms : Research Site
A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis
Bingham Farms : QUEST Research Institute
Multiple Sclerosis Spasticity Study
View More »
Ann Arbor : Universitly of Michigan
Masitinib in Patients With Primary Progressive or Relapse-free Secondary Multiple Sclerosis
Bingham Farms : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Bingham Farms : XenoPort Clinical Site
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Clinton Township : Investigational Site Number 840016 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Clinton TWP : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Clinton Twp : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Clinton Twp : Michigan Neurology Associates, P.C.
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Detroit : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Detroit : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Detroit : XenoPort Clinical Site
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Detroit : Henry Ford Health System
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Farmington Hills : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Farmington Hills : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Farmington Hills : Research Site
An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
Farmington Hills : Michigan Institute For Neurological Disorders
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Grand Rapids : Investigational Site Number 8955 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Traverse City : Investigational Site Number 8949 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Minnesota
Minneapolis : University of Minnesota
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
View More »
Edina : Minneapolis Clinic of Neurology
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Mississippi
Hattiesburg : Hattiesburg Clinic Neurological Research Center
Study of the effect on cognitive performance, safety and tolerability of SAR110894D at doses of 0.5 mg, 2 mg and 5 mg/day for 24 weeks in patients with mild to moderate Alzheimer's Disease on stable donepezil therapy
Missouri
Kansas City : Saint Luke's Hospital
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Saint Louis : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Springfield : St.John's Research Institute, Inc
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
St Louis : Investigational Site Number 840030 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
St Louis : Investigational Site Number 840031 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
View More »
St Louis : Investigational Site Number 8937 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
St. Louis : Washington University (John L. Trotter MS Center)
Ampyra for Optic Neuritis in MS
Montana
Great Falls : Advanced Neurology Specialists
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Great Falls : Benefis Physician Associates
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Missoula : Investigational Site Number 840009 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Nebraska
Lincoln : Neurology Associates PC
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
New Hampshire
Lebanon : Dartmouth Hitchcock Medical Center
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
View More »
Lebanon : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
New Jersey
Toms River : Research Site
A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis
View More »
Freehold : CentraState Medical Center.
Masitinib in Patients With Primary Progressive or Relapse-free Secondary Multiple Sclerosis
Newark : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Newark : UMDNJ
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Teaneck : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Teaneck : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Toms River : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Toms River : XenoPort Clinical Site
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
New Mexico
Albuquerque : Research Site
A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis
View More »
Albuquerque : XenoPort Clinical Site
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Albuquerque : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Albuquerque : Investigational Site Number 840023 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
New York
Buffalo : Jacobs Neurological Institute
Buffalo General Hospital
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
Mineola : Winthrop University Hospital Clinical Trials Center
Multiple Sclerosis - (MS) Primary Progressive Multiple Sclerosis
New York : Judith Jaffe Multiple Sclerosis Center
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
Patchogue : Research Site
A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis
Plainview : Research Site
A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis
View More »
Albany : Upstate Clinical Research, LLC
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Albany : Neurological Associates of Albany, PC
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Amherst : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Buffalo : Research Site
Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance
Buffalo : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Latham : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Latham : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Latham : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Latham : Research Site Updated
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Latham : Empire Neurology, PC
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
New York : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
New York : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
New York : Investigational Site Number 8925 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
New York : NYU-Hospital for Joint Diseases
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
New York : Mount Sinai School of Medicine
Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks
Patchogue : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Patchogue : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Patchogue : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Patchogue : XenoPort Clinical Site
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Patchogue : Research Site Updated
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Patchogue : South Shore Neurologic Associates
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Plainview : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Plainview : XenoPort Clinical Site
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Plainview : Research Site Updated
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Plainview : Island Neurological Associates
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Rochester : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Rochester : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Rochester : University of Rochester
Lubiprostone in Patients With Multiple Sclerosis Associated Constipation
Rochester : University of Rochester
Memantine for Spasticity in MS Patients
Rochester : University of Rochester
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Rochester : University of Rochester Medical Center
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Stony Brook : Stony Brook University
Mindfulness Based Stress Reduction in Multiple Sclerosis (MS)
Stony Brook : SUNY at Stony Brook
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
North Carolina
Asheville : Research Site
A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis
Chapel Hill : University of North Carolina
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
Hickory : PMG Research of Hickory
Do you have Multiple Scerosis (MS)?
Hickory : PMG Research of Hickory
Do You Have Multiple Sclerosis (MS)?
Winston Salem : PMG Research of Winston-Salem
Have you been diagnosed with a relapsing form of Multiple Sclerosis?
View More »
Advance : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Advance : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Advance : Investigational Site Number 840039 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Advance : Research Site Updated
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Advance : Cornerstone Research Care
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Asheville : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Asheville : XenoPort Clinical Site
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Charlotte : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Charlotte : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Charlotte : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Charlotte : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Charlotte : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Charlotte : Investigational Site Number 840027 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Charlotte : Neuroscience and Spine Institute/MS Center
Masitinib in Patients With Primary Progressive or Relapse-free Secondary Multiple Sclerosis
Charlotte : Investigational Site Number 8941 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Charlotte : The Neurological Institute, PA
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Charlotte : Teva Investigational Site 10198 Updated
To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS
Charlotte, : Carolinas Medical Center
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Hickory : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Hickory : Teva Investigational Site 10203 Updated
To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS
High Point : Cornerstone Neurology
NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness
Raleigh : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Raleigh : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Winston Salem : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Winston-Salem : Research Site Updated
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
North Dakota
Bismarck : Legacy Pharma Research
MS - Central Neuropathic Pain due to Multiple Sclerosis
Bismarck : Legacy Pharma Research
MS - Central Neuropathic Pain due to Multiple Sclerosis
View More »
Bismark : Investigational Site Number 840006 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Fargo : Investigational Site Number 840007 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Grand Forks : Research Site Updated
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Ohio
Akron : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Akron : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Akron : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Akron : XenoPort Clinical Site
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Akron : Teva Investigational Site 10194 Updated
To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS
View More »
Cincinnati : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Cleveland : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Cleveland : Cleveland Clinic Foundation
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Columbus : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Dayton : Research Site
An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
Dayton : Investigational Site Number 840046 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Dayton : Research Site Updated
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Dayton : Investigational Site Number 8924 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Dayton : Neurology Specialists, Inc.
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Gahanna : Research Site Updated
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Toledo : Investigational Site Number 840017 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Uniontown : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Uniontown : Research Site Updated
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Uniontown : Teva Investigational Site 10200 Updated
To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS
Oklahoma
Oklahoma City : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Oklahoma City : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Oklahoma City : Oklahoma Medical Research Foundation
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Tulsa : Investigational Site Number 840043 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Oregon
Portland : Providence St. Vincent Medical Center
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
View More »
Corvallis : The Corvallis Clinic, P.C.
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Medford : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Portland : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Portland : Oregon Health and Science University
Dalfampridine for Imbalance in Multiple Sclerosis
Portland : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Portland : Providence Multiple Sclerosis Center
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Pennsylvania
Abington : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Abinton : Research Site Updated
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Allentown : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Allentown : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Greensburg : Westmoreland Neurology
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
View More »
Philadelphia : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Philadelphia : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Philadelphia : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Philadelphia : Investigational Site Number 8956 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Philadelphia : University of Pennsylvania Health System
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Pittsburg : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Pittsburgh : Research Protocol Management Solutions
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Rhode Island
Providence : CNS Research of RI, Inc.
A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis.
Providence : The Neurology Foundation, Inc.
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
View More »
Providence : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Providence : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Providence : Neurology Foundation
Masitinib in Patients With Primary Progressive or Relapse-free Secondary Multiple Sclerosis
South Carolina
Greenville : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Tennessee
Franklin : Research Site
A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis
Franklin : Advanced Neurosciences Institute
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
Nashville : Research Site
A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis
View More »
Franklin : Research Site
An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
Franklin : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Franklin : XenoPort Clinical Site
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Franklin : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Franklin : Advanced Neurosciences Institute
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Knoxville : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Knoxville : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Memphis : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Memphis : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Nashville : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Nashville : XenoPort Clinical Site
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Nashville : Investigational Site Number 840002 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Round Rock : Investigational Site Number 840040 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Round Rock : Investigational Site Number 8905 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Texas
San Antonio : Research Site
A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis
View More »
Dallas : Baylor Research Institute
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Dallas : University of Texas Southwestern
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Dallas : UT Southwestern
Trial of Memantine for Cognitive Impairment in Multiple Sclerosis
Houston : Baylor College of Medicine
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Lubbock : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Round Rock : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Round Rock : Research Site Updated
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Round Rock : Central Texas Neurology
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Round Rock : Central Texas Neurology Consultants, P.A.
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
San Antonio : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
San Antonio : XenoPort Clinical Site
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
San Antonio : Investigational Site Number 840020 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
San Antonio : Innovative Clinical Trials, Bexar Diagnostic Medicine Assoc.
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Sherman : Texoma Neurology Associates
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Utah
Salt Lake City : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Salt Lake City : Research Site Updated
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Salt Lake City : Rocky Mountain MS Clinic
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Vermont
Burlington : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Burlington : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Burlington : Investigational Site Number 8930 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Virginia
Charlottesville : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Fairfax : Neurology Center of Fairfax
Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire
Newport New : Research Site Updated
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Norfolk : Research Site Updated
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Richmond : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
View More »
Vienna : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Vienna : XenoPort Clinical Site
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Vienna : Investigational Site Number 840032 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Vienna : MS Center of Greater Washington
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Washington
Seattle : Benaroya Research Institute at Virginia Mason
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
Tacoma : Research Site
A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis
View More »
Kirkland : MS Center at Evergreen
A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis
Kirkland : Evergreen Healthcare
A Study to Test the Use of Duloxetine for Pain in MS
Kirkland : MS Center at Evergreen Healthcare
Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients With Multiple Sclerosis Taking Glatiramer Acetate
Kirkland : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Seattle : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Seattle : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Seattle : Research Site Updated
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Seattle : Investigational Site Number 8963 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Seattle : Swedish Medical Center
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Seattle : Swedish Neuroscience Institute
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Seattle : Pacific Medical Centers
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Seattle : MS Hub
Trial of Memantine for Cognitive Impairment in Multiple Sclerosis
Tacoma : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Tacoma : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Tacoma : XenoPort Clinical Site
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Tacoma : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Tacoma : Research Site Updated
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Tacoma : MultiCare Health System
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Tacoma : MultiCare Research Institute
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
West Virginia
Wisconsin
Milwaukee : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Milwaukee : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Milwaukee : Aurora Health Care
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Albania
Many Locations :
Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis
Argentina
Argentina : Investigational Site Number 032002 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Buenos Aires : Investigational Site Number 032003 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Buenos Aires : Fundación Argentina Contra las Enfermedades Neurológicas del Envejecimiento - FACENE
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Caba : Investigational Site Number 032004 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Ciudad Autonoma de Buenos Aires : Medeos - Centro de Medicina Integral e Investigación Clínica
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
View More »
Ciudad Autonoma de Buenos Aires : Instituto de Neurologia Cognitiva
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Ciudad Autónoma de Buenos Aires : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Ciudad de Buenos Aires : Instituto Argentino de Investigacion Neurologica
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Godoy Cruz : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Rosario : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Australia
Adelaide : Merck Serono Research Site
Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.
Auchenflower : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Ballarat : Investigational Site Number 036009 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Bedford Park : Investigational Site Number 036008 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Bedford Park : Investigational Site Number 1408 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
View More »
Box Hill : Merck Serono Research Site
Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.
Bruce : Merck Serono Research Site
Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.
Chatswood : Investigational Site Number 036005 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Chatswood : Merck Serono Research Site
Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.
Clayton : Merck Serono Research Site
Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.
Concord : Investigational Site Number 036003 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Fitzroy : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Fitzroy : St Vincent's Hospital
Open-Label Study to Assess the Effect of Fampridine-PR on Quality of Life as Reported by Subjects With Multiple Sclerosis
Fitzroy : Merck Serono Research Site
Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.
Footscray : Merck Serono Research Site
Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.
Geelong : Investigational Site Number 1405 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Geelong : Merck Serono Research Site
Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.
Gold Coast : Investigational Site Number 1409 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Heidelberg : Investigational Site Number 1404 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Heidelberg : Merck Serono Research Site
Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.
Heidelberg West : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Heidelberg West : Investigational Site Number 036001 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Hobart : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Hobart : Investigational Site Number 1407 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Kogarah : Investigational Site Number 036004 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
New Lambton : Investigational Site Number 036010 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Orange : Merck Serono Research Site
Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.
Parkville : Investigational Site Number 1401 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Perth : Merck Serono Research Site
Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.
St Leonards : Investigational Site Number 036002 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Woollongong : Merck Serono Research Site
Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.
Austria
Graz : Investigational Site Number 040001 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Innsbruck : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Innsbruck : Investigational Site Number 4004 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Linz : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Linz : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
View More »
Linz : Investigational Site Number 040004 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Linz : Investigational Site Number 4005 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Linz : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Many Locations : Updated
Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis
Salzburg : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Salzburg : Investigational Site Number 040003 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Vienna : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Wien : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Wien : Investigational Site Number 040002 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Wien : Investigational Site Number 4001 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Belgium
Antwerpen : Research Site
Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study
Brabant Wallon : Research Site
Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study
Brasschaat : Research Site
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS
Brugge : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Bruxelles : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
View More »
Bruxelles : Research Site
Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study
Charleroi : Investigational Site Number 056005 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Esneux : Centre Hospitalier Universitaire de Liège Ourthe Ambléve
Efficacy of Clean Intermittent Catheterization in MS Patients With Bladder Dysfunction
Gent : Investigational Site Number 056004 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Hainaut : Research Site
Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study
Hasselt : Investigational Site Number 056003 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
La Louviere : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
La Louvière : Investigational Site Number 056006 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Leuven : Investigational Site Number 056002 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Leuven : UZ Gasthuisberg
Efficacy of Clean Intermittent Catheterization in MS Patients With Bladder Dysfunction
Liege : Research Site
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS
Liège : Research Site
Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study
Liège : Centre Hospitalier Universitaire de Liège
Open-Label Study to Assess the Effect of Fampridine-PR on Quality of Life as Reported by Subjects With Multiple Sclerosis
Limburg : Research Site
Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study
Luxembourg : Research Site
Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study
Many Locations : Updated
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Many Locations : Updated
Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis
Oost-Vlaanderen : Research Site
Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study
Sijsele-damme : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Sijsele-Damme : Investigational Site Number 056001 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
West-Vlaanderen : Research Site
Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study
Wilrijk : Investigational Site Number 056007 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Wilrijk : Research Site
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS
Bosnia and Herzegovina
Many Locations : Updated
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Sarajevo : Teva Investigational Site 69001 Updated
To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS
Tuzla : Teva Investigational Site 69003 Updated
To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS
Brazil
Belo Horizonte : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Brasilia : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Campinas : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Joinville : Investigational Site Number 076009 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Passo Fundo : Investigational Site Number 076012 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
View More »
Porto Alegre : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Porto Alegre : Investigational Site Number 076003 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Porto Alegre : Investigational Site Number 076005 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Recife : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Recife : Investigational Site Number 076010 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Ribeirão Preto : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Rio de Janeiro : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Sao Paulo : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Sao Paulo : Investigational Site Number 076007 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Bulgaria
Pleven : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Pleven : Investigational Site Number 5312 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Plovdiv : Synthon investigational site 206
Efficacy and Safety of GTR in Comparison to Copaxone®
Sofia : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Sofia : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
View More »
Sofia : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Sofia : Synthon investigational site 202
Efficacy and Safety of GTR in Comparison to Copaxone®
Sofia : Synthon investigational site 203
Efficacy and Safety of GTR in Comparison to Copaxone®
Sofia : Synthon investigational site 205
Efficacy and Safety of GTR in Comparison to Copaxone®
Sofia : GSK Investigational Site Updated
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
Sofia : Investigational Site Number 5303 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Sofia : Investigational Site Number 5304 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Sofia : Investigational Site Number 5307 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Sofia : Investigational Site Number 5309 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Varna : Synthon investigational site 201
Efficacy and Safety of GTR in Comparison to Copaxone®
Canada
Burlington : Central Contact
Canadian Avonex PEN Productivity Study
Burnaby : Research Site
JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)
Calgary : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Calgary : Investigational Site Number 124005 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Calgary : Research Site
JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)
View More »
Cambridge : Research Site
JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)
Chicoutimi : Research Site
JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)
Edmonton : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Edmonton : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Edmonton : Investigational Site Number 124004 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Edmonton : Research Site
JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)
Edmonton : GSK Investigational Site Updated
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
Gatineau : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Gatineau : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Gatineau : Investigational Site Number 124003 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Gatineau : Research Site
JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)
Greenfield Park : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Greenfield Park : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Greenfield Park : Investigational Site Number 5402 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Guelp : Research Site
JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)
Halifax : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Halifax : Research Site
JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)
Hamlton : Research Site
JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)
Kingston : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Kingston : Investigational Site Number 124006 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
London : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
London : Research Site
JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)
London : Investigational Site Number 5403 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Montreal : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Montreal : Investigational Site Number 124007 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Montreal : Research Site
JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)
Montreal : GSK Investigational Site Updated
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
Montréal : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Ottawa : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Ottawa : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Ottawa : Investigational Site Number 124008 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Ottawa : Research Site
JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)
Ottawa : Investigational Site Number 5401 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Quebec : Research Site
JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)
Quebec : Investigational Site Number 5406 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Regina : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Regina : Investigational Site Number 124002 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Riviere-Du-Loup : Research Site
JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)
Saint John : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Saint John : Research Site
JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)
Saskatoon : Research Site
JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)
Sherbrooke : Investigational Site Number 124001 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Sherbrooke : Investigational Site Number 5408 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
St Johns : Research Site
JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)
Sydney : Research Site
JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)
Thunder Bay : Research Site
JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)
Toronto : Research Site
JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)
Toronto : Investigational Site Number 5404 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Toronto : Investigational Site Number 5410 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Trois-Rivieres : Research Site
JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)
Vancouver : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Vancouver : Vancouver Coastal Health: University of British Columbia Hospital
Effect of Aerobic Exercise on Side Effects of Disease Modifying Therapy With Subcutaneous Interferon-b1b in Patients With Multiple Sclerosis
Vancouver : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Vancouver : Research Site
JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)
Vancouver : MS Clinic UBC Hospital
Pharmacogenomics of Drug Safety in Multiple Sclerosis
Vancouver : University of British Columbia
Treatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis Subjects
Winnipeg : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Winnipeg : Health Sciences Centre Multiple Sclerosis Clinic
Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple Sclerosis
Winnipeg : Investigational Site Number 124009 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Winnipeg : Research Site
JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)
Chile
Santiago : Investigational Site Number 152003 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Santiago : Investigational Site Number 152004 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Santiago : Investigational Site Number 1525601 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Santiago : Investigational Site Number 1525602 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Viña Del Mar : Investigational Site Number 152002 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
View More »
Viña Del Mar : Investigational Site Number 152005 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Viña Del Mar : Investigational Site Number 1525605 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
China
Many locations :
China Betaferon Adherence, Coping and Nurse Support Study
Many Locations : Updated
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Nanjing : Nanjing University Medical College Affiliated Drum Tower Hospital
Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica
Colombia
Barranquilla : Investigational Site Number 170001 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Bogota : Investigational Site Number 170005 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Bogota : Investigational Site Number 170002 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Bogota : Investigational Site Number 170006 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Bogota : Investigational Site Number 170007 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
View More »
Bucaramanga : Investigational Site Number 170004 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Many Locations : Updated
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Medellin : Investigational Site Number 170009 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Croatia
Varazdin : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Zagreb : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Zagreb : Teva Investigational Site 60001 Updated
To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS
Zagreb : Teva Investigational Site 60002 Updated
To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS
Zagreb : Teva Investigational Site 60006 Updated
To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS
Czech Republic
Brno : Research Site
An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
Brno : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Brno : Investigational Site Number 5801 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Brno : Research Site
Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing Remitting Multiple Sclerosis
Brno-bohunice : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
View More »
Hradec Kralove : Novartis Investigative Site
A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis
Hradec Kralove : Research Site
An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
Hradec Kralove : Research Site
Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing Remitting Multiple Sclerosis
Jihlava : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Jihlava : Research Site
An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
Jihlava : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Jihlava : GSK Investigational Site Updated
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
Many Locations : Updated
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Olomouc : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Olomouc : Investigational Site Number 5804 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Ostrava : Research Site
An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
Ostrava - Poruba : Investigational Site Number 5805 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Pardubice : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Pardubice : Research Site
An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
Prague : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Praha : Novartis Investigative Site
A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis
Praha 10 : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Praha 2 : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Praha 2 : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Teplice : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Teplice : Research Site
An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
Teplice : Research Site
Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing Remitting Multiple Sclerosis
Denmark
Aarhus C : Investigational Site Number 208002 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Aarhus C : MS Clinic, Department of Neurology, Aarhus University Hospital
Multiple Sclerosis and Progressive Resistance Training
Aarhus C : Sport Science, Aarhus University
Multiple Sclerosis and Progressive Resistance Training
Aarhus C : Investigational Site Number 6002 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Copenhagen : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
View More »
Esbjerg : Research Site
A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Patients With Multiple Sclerosis
Esbjerg : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Glostrup : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Glostrup : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Glostrup : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
København : Dansk Multipel Sclerose Center
Open-Label Study to Assess the Effect of Fampridine-PR on Quality of Life as Reported by Subjects With Multiple Sclerosis
København Ø : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Koebenhavn Ø : GSK Investigational Site Updated
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
Odense : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Odense C : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Sønderborg : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Vejle : Research Site
A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Patients With Multiple Sclerosis
Vejle : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Viborg : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Egypt
Many Locations : Updated
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Estonia
Many Locations : Updated
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Tallinn : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Tallinn : Investigational Site Number 233002 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Tallinn : Investigational Site Number 6201 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Tallinn : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
View More »
Tartu : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Tartu : Investigational Site Number 233001 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Tartu : Investigational Site Number 6203 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Finland
Helsinki : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Helsinki : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Helsinki : Investigational Site Number 246003 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Helsinki : Investigational Site Number 6405 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Helsinki : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
View More »
Helsinski : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Hyvinkää : Investigational Site Number 246006 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Jyväskylä : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Jyväskylä : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Many Locations : Updated
Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis
Oulu : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Oulu : Investigational Site Number 246004 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Pori : Investigational Site Number 246002 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Seinäjoki : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Tampere : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Tampere : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Tampere : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Tampere : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Tampere : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Turku : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Turku : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Turku : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Turku : Investigational Site Number 246001 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Turku : Investigational Site Number 6401 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Turku : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
France
Agen : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Aix En Provence : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Amiens : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Amiens : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Angers : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
View More »
Auxerre : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Avignon : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Bayonne : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Belfort : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Besancon : Investigational Site Number 250003 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Besancon : Investigational Site Number 6611 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Beziers : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Bobigny : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Bobigny : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Bordeaux : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Bordeaux : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Bordeaux : Service de Neurologie - Pôle des Neurosciences Cliniques, CHU de Bordeaux.
Randomised Controlled Clinical Trial of Cognitive Rehabilitation in Multiple Sclerosis
Boulogne Sur Mer : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Bourdeaux : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Brest : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Bron : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Caen : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Caen Cedex 5 : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Calais : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Castelnau Le Lez : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Chambray Les Tours : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Cherbourg Octeville : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Clermont Ferrand : Hôpital Gabriel Montpied
Masitinib in Patients With Primary Progressive or Relapse-free Secondary Multiple Sclerosis
Clermont Ferrand Cedex 1 : Investigational Site Number 250010 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Clermont Ferrand Cedex 1 : Investigational Site Number 6601 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Clermont-ferrand : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Clermont-ferrand : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Dijon : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Dijon : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Epinal : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Garches : Hopital Raymond Poincaré
Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
Grenoble : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Haguenau : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
La Rochelle : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
La Seyne Sur Mer : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Le Kremlin Bicetre : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Le Mans : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Lille : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Lille : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Lille : Hôpital Roger Salengro
Masitinib in Patients With Primary Progressive or Relapse-free Secondary Multiple Sclerosis
Lille Cedex : Investigational Site Number 250005 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Lille Cedex : Investigational Site Number 6609 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Limoges : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
L'union : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Lyon : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Lyon : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Lyon Cedex 03 : Investigational Site Number 250002 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Many Locations : Updated
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Marseille : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Marseille : Hopital de la conception
Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
Marseille : La Timone University Hospital (APHM)
The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.
Marseille Cedex 9 : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Metz : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Montauban : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Montbeliard : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Montpellier : CHU Hôpital Gui de Chauliac Service de Neurologie B
A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly
Montpellier : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Montpellier : Hôpital Guy de Chauliac
Masitinib in Patients With Primary Progressive or Relapse-free Secondary Multiple Sclerosis
Montpellier Cedex 05 : Investigational Site Number 6604 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Montpellier Cedex 5 : Investigational Site Number 250004 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Mulhouse : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Nancy : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Nancy : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Nancy Cedex : Investigational Site Number 250001 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Nancy Cedex : Investigational Site Number 6612 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Nantes : CHU Hotel Dieu
Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
Nantes Cedex 01 : Investigational Site Number 250006 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Nantes Cedex 01 : Investigational Site Number 6605 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Nice : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Nice : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Nice Cedex : Investigational Site Number 6602 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Nimes : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Nimes : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Nimes : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Nimes : Investigational Site Number 6614 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Orleans : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Orsay : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Paris : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Paris : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Paris : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Paris : Hopital Tenon
Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
Paris : La Pitie-Salpaetriere Hospital (APHP)
The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.
Paris Cedex 20 : Investigational Site Number 250007 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Paris Cedex 5 : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Pau : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Poissy : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Poitiers : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Pontoise : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Quimper : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Reims : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Reims : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Reims : Maison Blanche Hospital
The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.
Rennes : Rennes University Hospital
The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.
Roanne : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Rouen : CHU Rouen - Hopital Charles Nicolle
Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
Sainte Foy Les Lyon : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Saumur : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
St Aubin Sur Scie : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Strasbourg : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Strasbourg : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Strasbourg : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Strasbourg : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Strasbourg : Nouvel Hôpital Civil, Clinique Neurologique
Open-Label Study to Assess the Effect of Fampridine-PR on Quality of Life as Reported by Subjects With Multiple Sclerosis
Strasbourg Cedex : Investigational Site Number 6607 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Talant : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Toulouse : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Toulouse : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Toulouse : CHU Toulouse - Hopital Rangueil
Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
Toulouse : Purpan Hospital
The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.
Toulouse Cedex 3 : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Tourcoing : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Tours : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Vichy : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Georgia
Tbilisi : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Tbilisi : XX
Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Germany
Aachen : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Achim : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Achim : GSK Investigational Site Updated
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
Asbach : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Aschaffenburg : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
View More »
Bad Mergentheim : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Bad Mergentheim : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Bad Mergentheim : Investigational Site Number 276009 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Bad Neustadt / Saale : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Bad Wilbad : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Baesweiler : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Bamberg : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Bamberg : Investigational Site Number 276020 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Bamberg : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Bamberg : Novartis Investigative Site
Zoledronic Acid in MS-patients With Osteoporosis
Bayreuth : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Bayreuth : Investigational Site Number 276003 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Bayreuth : Investigational Site Number 6801 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Berg-kemptenhausen : Research Site
An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra® When Used In Routine Medical Practice
Berlin : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Berlin : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Berlin : Novartis Investigative Site
Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod
Berlin : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Berlin : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Berlin : Investigational Site Number 276015 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Berlin : Investigational Site Number 276016 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Berlin : Investigational Site Number 276021 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Berlin : Investigational Site Number 276007 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Berlin : St. Hedwig Hospital, Department of Urology
Efficacy of Clean Intermittent Catheterization in MS Patients With Bladder Dysfunction
Berlin : NeuroCure Clinical Research Center, Charité Berlin
Flupirtine as Oral Treatment in Multiple Sclerosis
Berlin : GSK Investigational Site Updated
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
Berlin : Morphosys Investigative Site
Phase Ib Study to Evaluate the Safety and Pharmacokinetics of MOR103, a Human Antibody to GM-CSF, in Patients With Multiple Sclerosis
Berlin : Investigational Site Number 6805 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Berlin : Investigational Site Number 6810 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Berlin : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Berlin : Novartis Investigative Site
Zoledronic Acid in MS-patients With Osteoporosis
Bielefeld : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Bielefeld : Novartis Investigative Site
Zoledronic Acid in MS-patients With Osteoporosis
Böblingen : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Bochum : Research Site
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS
Bochum : GSK Investigational Site Updated
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
Bochum : Novartis Investigative Site
Pregnancy Registry Trial
Bochum : Novartis Investigative Site
Zoledronic Acid in MS-patients With Osteoporosis
Bogen : Novartis Investigative Site
Zoledronic Acid in MS-patients With Osteoporosis
Bonn : Investigational Site Number 276012 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Butzbach : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Dresden : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Dresden : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Dresden : Investigational Site Number 276005 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Dresden : Research Site
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS
Dresden : Novartis Investigative Site
Zoledronic Acid in MS-patients With Osteoporosis
Düsseldorf : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Düsseldorf : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Düsseldorf : Investigational Site Number 276032 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Düsseldorf : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Erbach : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Erbach : Investigational Site Number 276018 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Erbach : Investigational Site Number 6807 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Erfurt : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Erlangen : Investigational Site Number 276004 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Erlangen : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Essen : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Frankfurt : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Frankfurt : Research Site
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS
Frankfurt Am Main : Investigational Site Number 276025 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Freiburg : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Freiburg : Investigational Site Number 276028 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Freiburg : Research Site
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS
Freiburg : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
GIEßEN : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Gießen : Investigational Site Number 276006 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Göttingen : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Göttingen : University of Göttingen, Department of Neurology
Flupirtine as Oral Treatment in Multiple Sclerosis
Hamburg : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Hamburg : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Hamburg : Investigational Site Number 276010 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Hamburg : GSK Investigational Site Updated
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
Hamburg : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Hannover : Investigational Site Number 6809 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Hannover : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Heidelberg : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Heidelberg : Novartis Investigative Site
Zoledronic Acid in MS-patients With Osteoporosis
Hennigsdorf : Investigational Site Number 276022 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Ingolstadt : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Jena : Research Site
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS
Jena : Univeristaetsklinikum Jena
Open-Label Study to Assess the Effect of Fampridine-PR on Quality of Life as Reported by Subjects With Multiple Sclerosis
Kandel : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Kassel : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Kassel : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Kassel : Investigational Site Number 276024 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Kassel : Novartis Investigative Site
Zoledronic Acid in MS-patients With Osteoporosis
Koeln : GSK Investigational Site Updated
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
Köln : Investigational Site Number 6813 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Köln : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Leipzig : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Leipzig : Investigational Site Number 276001 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Leipzig : Novartis Investigative Site
Zoledronic Acid in MS-patients With Osteoporosis
Leverkusen : Novartis Investigative Site
Zoledronic Acid in MS-patients With Osteoporosis
Ludwigshafen : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Ludwigshafen : Investigational Site Number 6804 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Mainz : Investigational Site Number 276013 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Many Locations : Updated
Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)
Many Locations :
Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis
Many Locations : Updated
Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis
Marburg : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Marburg : Research Site
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS
Minden : Investigational Site Number 276023 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Minden : Novartis Investigative Site
Zoledronic Acid in MS-patients With Osteoporosis
Muenchen : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Muenster : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
München : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
München : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Munich : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Munster : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Münster : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Münster : Investigational Site Number 276002 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Münster : Investigational Site Number 6802 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Münster : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Oldenburg : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Osnabrück : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Prien : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Regensburg : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Regensburg : Investigational Site Number 6814 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Regensburg : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Rostock : Investigational Site Number 276031 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Rostock : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Siegen : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Siegen : Novartis Investigative Site
Zoledronic Acid in MS-patients With Osteoporosis
Stuttgart : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Stuttgart : Novartis Investigative Site
Zoledronic Acid in MS-patients With Osteoporosis
Teupitz : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Tübingen : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Tübingen : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Tübingen : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Tuebingen : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
ULM : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
ULM : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Ulm : Research Site
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS
Ulm : University of Ulm, Department of Neurology
Flupirtine as Oral Treatment in Multiple Sclerosis
Ulm : Investigational Site Number 6812 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Wermsdorf : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Wermsdorf : Investigational Site Number 276014 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Westerstede : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Wiesbaden : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Wiesbaden : Investigational Site Number 276008 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Wiesbaden : Investigational Site Number 6806 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Wuppertal : Investigational Site Number 276026 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Würzburg : Investigational Site Number 276011 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Greece
Athens : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Athens : Henry Dunant Hospital - IRB
An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters
Athens : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Athens : Investigational Site Number 300001 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Athens : Investigational Site Number 300002 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
View More »
Heraklion : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Heraklion : Investigational Site Number 300003 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Ioannina : Investigational Site Number 300004 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Larissa : Investigational Site Number 300005 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Thessaloniki : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Thessaloniki : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Thessaloniki : Investigational Site Number 300006 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Hungary
Budapest : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Budapest : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Budapest : Research Site
An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
Budapest : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Budapest : Investigational Site Number 348006 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
View More »
Budapest : Investigational Site Number 348010 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Budapest : Investigational Site Number 348002 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Budapest : Investigational Site Number 7101 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Budapest : Investigational Site Number 7103 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Budapest : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Debrecen : Research Site
An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
Eger : Research Site
An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
Eger : Investigational Site Number 348009 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Esztergom : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Esztergom : Research Site
An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
Esztergom : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Esztergom : Investigational Site Number 348003 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Gyor : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Kaposvár : Investigational Site Number 348008 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Miskolc : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Nyiregyhaza : Research Site
An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
Nyíregyháza : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Pécs : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Pécs : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Szeged : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Szeged : Investigational Site Number 348001 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Szeged : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Szekesfehervar : Investigational Site Number 348005 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Székesfehérvár : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Veszprem : Research Site
An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
Veszprém : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Veszprém : Investigational Site Number 348011 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Veszprém : Investigational Site Number 7105 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Zalaegerszeg : Investigational Site Number 348007 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
India
Bangalore : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Delhi : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Hyderabad : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Mumbai : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Nagpur : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
View More »
New Delhi : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Trivandrum : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Ireland
Dublin : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Israel
Ashkelon : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Ashkelon : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Haifa : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Kfar Saba : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Many Locations : Updated
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
View More »
Petach Tikva : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Petach Tikva : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Ramat-gan : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Safed : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Tzfat : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Tzrifin : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Italy
Ancona : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg
Ancona : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Bari : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Barletta : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg
Bergamo : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
View More »
Bolzano : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg
Cagliari : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Cagliari : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Cagliari : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg
Caltanissetta : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg
Catania : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Catania : Investigational Site Number 380009 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Catania : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg
Catania : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Catanzaro : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Cefalu : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Cefalù : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Cefalù : Investigational Site Number 380002 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Cefalù : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Chieti : Research Site
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS
Como : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg
Cuneo : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg
Empoli : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg
Fidenza : Investigational Site Number 380003 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Fidenza : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Firenze : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Firenze : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Foggia : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg
Gallarate : Investigational Site Number 380004 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Gallarate : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Genova : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Genova : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Genova : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg
Genova : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Imperia : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg
L'Aquila : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg
Lecce : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg
Legnago : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg
Many Locations : Updated
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Merano : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg
Messina : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg
Messina : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Milan : Institute of Experimental Neurology
Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity
Milano : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Milano : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Milano : Investigational Site Number 380001 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Milano : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg
Milano : Novartis Investigational Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg
Milano : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Milano : Ospedale San Raffaele
Open-Label Study to Assess the Effect of Fampridine-PR on Quality of Life as Reported by Subjects With Multiple Sclerosis
Modena : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg
Montichiari : Investigational Site Number 380012 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Napoli : Investigational Site Number 380011 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Napoli : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg
Napoli : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Novara : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg
Orbassano : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Orbassano : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Orbassano : Investigational Site Number 380007 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Padova : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Padova : Investigational Site Number 380006 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Padova : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Palermo : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg
Pavia : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Pavia : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Perugia : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg
Pisa : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg
Reggio Calabria : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg
Roma : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Roma : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Roma : Investigational Site Number 380008 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Roma : Investigational Site Number 380005 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Roma : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Rome : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
San Donato Milanese : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg
Trieste : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg
Verona : Investigational Site Number 380014 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Verona : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg
Japan
Chiba, : Research Site
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Chiba, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Fukuoka, : Research Site
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Fukuoka, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Hiroshima, : Research Site
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
View More »
Hiroshima, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Kawagoe, : Research Site
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Kawagoe, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Kodaira, : University of British Columbia
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Kodaira, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Kyoto, : Research Site
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Kyoto, : London Health Sciences Centre
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Kyoto, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Morioka, : Research Site
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Morioka, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Niigata, : Research Site
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Niigata, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Osaka, : Univ of Calgary / Foothills MC
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Osaka, : Research Site
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Osaka, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Sapporo, : Research Site
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Sapporo, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Sendai, : Research Site
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Sendai, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Suita, : Research Site
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Suita, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Tokorozawa, : Research Site
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Tokorozawa, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Tokyo, : Research Site
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Tokyo, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Tsukuba, : Research Site
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Tsukuba, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Ube, : Research Site
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Ube, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Yokohama, : Research Site
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Yokohama, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Jordan
Many Locations : Updated
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Korea, Republic of
Goyang-Si : Investigational Site Number 410002 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Many Locations :
Betaferon® Regulatory Post-Marketing Surveillance
Many Locations : Updated
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Seoul : Investigational Site Number 410001 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Seoul : Investigational Site Number 410003 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
View More »
Seoul : Investigational Site Number 410004 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Seoul : Investigational Site Number 410005 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Kuwait
Many Locations : Updated
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Latvia
Riga : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Riga : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Lebanon
Many Locations : Updated
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Libyan Arab Jamahiriya
Many Locations : Updated
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Lithuania
Kaunas : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Kaunas : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Kaunas : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Klaipeda : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Klaipeda : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
View More »
Klaipeda : Investigational Site Number 7402 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Siauliai : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Siauliai : Investigational Site Number 7403 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Vilnius : Investigational Site Number 7401 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Malaysia
Kuala Lumpur : Novartis Investigative Site
Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
Penang : Novartis Investigative Site
Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
Mexico
Aguascalientes : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Aguascalientes : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Chihuahua : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Guadalajara : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Many Locations : Updated
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
View More »
Mexico : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Mexico : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Tijuana : Hospital Angeles
Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple Sclerosis
Moldova, Republic of
Chisinau : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Netherlands
Amsterdam : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Amsterdam : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Breda : Investigational Site Number 528001 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Breda : Amphia Ziekenhuis
Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)
Breda : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
View More »
Eindhoven : Investigational Site Number 528003 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Eindhoven : Research Site
Open-Label Study to Assess the Effect of Fampridine-PR on Quality of Life as Reported by Subjects With Multiple Sclerosis
Eindhoven : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Gouda : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Leeuwarden : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Many Locations : Updated
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Nieuwegein : Investigational Site Number 528005 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Nieuwegein : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Nijmegen : UMC ST Radboud Nijmegen, Department of Urology
Efficacy of Clean Intermittent Catheterization in MS Patients With Bladder Dysfunction
Sittard : Research Site
An Observational Study to Assess Persistence, Adherence, Quality of Life, and Treatment Satisfaction in Patients Beginning Therapy With the Avonex® PEN™
Sittard : Maasland Ziekenhuis
Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)
Sittard : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Sittard-Geleen : Investigational Site Number 528002 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Venray : Investigational Site Number 528006 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Venray : GSK Investigational Site Updated
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
New Zealand
Christchurch : Primorus Clinical Trials, 40 Stewart Street
Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis
Hamilton : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Many Locations : Updated
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Norway
Bergen : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Lørenskog : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Many Locations : Updated
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Molde : Molde Hospital
An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra® When Used In Routine Medical Practice
Oslo : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
View More »
Oslo : Investigational Site Number 578001 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Oslo : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Sandvika : Sandvika Nevrosenter
A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects
Tønsberg : Investigational Site Number 578002 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Peru
Bellavista : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Lima : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Poland
Bialystok : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Bialystok : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Bialystok : Research Site
Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing Remitting Multiple Sclerosis
Bydgoszcz : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Bydgoszczas : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
View More »
Czestochowa : Teva Investigational Site 53020 Updated
To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS
Gdansk : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Gdansk : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Gdansk : Investigational Site Number 7709 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Gdansk : Research Site
Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing Remitting Multiple Sclerosis
Grudziadz : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Katowice : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Katowice : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Katowice : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Katowice : Research Site
An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
Katowice : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Katowice : Teva Investigational Site 53021 Updated
To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS
Kielce : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Kielce : Teva Investigational Site 53019 Updated
To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS
Konskie : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Krakow : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Krakow : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Krakow : Research Site
An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
Krakow : Research Site
Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing Remitting Multiple Sclerosis
Kraków : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Lodz : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Lodz : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Lodz : Investigational Site Number 7710 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Lodz : Research Site
Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing Remitting Multiple Sclerosis
Lodz : Coordinating Research Site
Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing Remitting Multiple Sclerosis
Lodz : Teva Investigational Site 53018 Updated
To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS
Lódz : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Lublin : Medical University, Department of Neurology
An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF)
Lublin : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Lublin : Research Site
Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing Remitting Multiple Sclerosis
Many Locations : Updated
Depression and Fatigue in MS Patients Treated With Betaferon.
Olsztyn : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Olsztyn : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Plewiska : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Poznan : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Poznan : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Poznan : Morphosys Investigative Site
Phase Ib Study to Evaluate the Safety and Pharmacokinetics of MOR103, a Human Antibody to GM-CSF, in Patients With Multiple Sclerosis
Poznan / Plewiska : Teva Investigational Site 53030 Updated
To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS
Szczecin : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Szczecin : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Szczecin : Teva Investigational Site 53026 Updated
To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS
Warszawa : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Warszawa : Investigational Site Number 7701 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Warszawa : Investigational Site Number 7703 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Warszawa 44 : Investigational Site Number 7707 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Portugal
Amadora : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Amadora : Investigational Site Number 620001 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Coimbra : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Coimbra : Investigational Site Number 620004 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Coimbra : Centro Hospitalar de Coimbra, EPE
Open-Label Study to Assess the Effect of Fampridine-PR on Quality of Life as Reported by Subjects With Multiple Sclerosis
View More »
Lisboa : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Lisbon : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Many Locations : Updated
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Porto : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Setubal : Investigational Site Number 620003 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Puerto Rico
Guaynabo : Caribbean Center for Clinical Research, Inc.
Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies
Romania
Bucharest : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Bucurest : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Bucuresti : Investigational Site Number 7803 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Bucuresti : Investigational Site Number 7806 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Cluj-Napoca : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
View More »
Cluj-Napoca : Investigational Site Number 7805 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Cluj-Napoca : Investigational Site Number 7807 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Iasi : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Târgu Mures : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Timisoara : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Timisoara : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Timisoara : Investigational Site Number 7808 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Russian Federation
Belgorod : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
Chelyabinsk : Municipal Healthcare Institution "City Clinical Hospital #3", Department of neurology
ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis
Chelyabinsk : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Ekaterinburg : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Kaluga : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
View More »
Kaluga : Investigational Site Number 643012 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Kazan : State Medical Institution "Republican Clinical Hospital of rehabilitation treatment of Ministry of Healthcare of Tatarstan Republic", Republican clinicodiagnostic center of demyelinating diseases of Ministry of Healthcare of Tatarstan Republic
ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis
Kazan : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Kazan : Investigational Site Number 643007 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Kazan : GSK Investigational Site Updated
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
Kazan : Investigational Site Number 7907 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Kemerovo : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Kemerovo : Investigational Site Number 643001 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Krasnoyarsk : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Moscow : State Educational Institution of Higher Professional Education "1st Moscow State Medical University n.a. I.M. Sechenov of Ministry of Healthcare and Social Development of the Russian Federation, Department of new drugs research
ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis
Moscow : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Moscow : Investigational Site Number 643013 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Moscow : GSK Investigational Site Updated
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
N. Novgorod : GSK Investigational Site Updated
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
Nizhny Novgorod : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Nizhny Novgorod : Investigational Site Number 643006 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Nizhny Novgorod : Investigational Site Number 643004 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Nizhny Novgorod : Investigational Site Number 7909 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Nizhny Novgorod : Investigational Site Number 7904 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Nizhny Novgorod : Investigational Site Number 7906 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Novosibirsk : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Novosibirsk : Investigational Site Number 643015 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Novosibirsk : Investigational Site Number 7912 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Perm : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Rostov-on-Don : State Healthcare Institution 'Rostov Regional Clinical Hospital' Center of Neurology
ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis
Rostov-on-Don : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Rostov-On-Don : Investigational Site Number 643009 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Rostov-On-Don : Investigational Site Number 643010 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Saint Petersburg : State Educational Institution of Higher Professional Education "St. Petersburg State Medical University n.a. I.V. Pavlov of Roszdrav", Department of neurology with clinic
ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis
Saint Petersburg : LLC "International Clinic MEDEM", Department of functional diagnostics
ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis
Saint Petersburg : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Samara : State Healthcare Institution "Samara Regional Clinical Hospital n.a. M.I. Kalinin", Department of neurosurgery
ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis
Samara : Investigational Site Number 643016 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Saratov : State Educational Institution of Higher Professional Education Saratov State Medical University
ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis
Smolensk : State Educational Institution of Higher Professional Education "Smolensk State Medical Academy of Roszdrav", Department of neurology and neurosurgery based at State Healthcare Institution "Smolensk Regional Clinical Hospital"
ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis
Smolensk : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Smolensk : Investigational Site Number 643005 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Smolensk : Investigational Site Number 7905 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
St Petersburg : St. Petersburg State Healthcare Institution "City multifield hospital #2", Department of neurology #2
ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis
St Petersburg : Institution of the Russian Academy of Science "Institute of Human Brain of RAS", Neuroimmunology Laboratory
ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis
St.Petersburg : GSK Investigational Site Updated
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
St-Petersburg : Investigational Site Number 643017 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
St-Petersburg : Investigational Site Number 643003 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
St-Petersburg : Investigational Site Number 643011 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
St-Petersburg : Investigational Site Number 643018 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
St-Petersburg : Investigational Site Number 643002 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
St-Petersburg : Investigational Site Number 7911 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Tomsk : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Tumen : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Ufa : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Yaroslavl : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Yaroslavl : Investigational Site Number 643014 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Saudi Arabia
Many Locations : Updated
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Serbia
Belgrade : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Kragujevac : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Nis : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Novi Sad : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Slovakia
Banska Bystrica : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Bratislava : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Many Locations : Updated
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Martin : Investigational Site Number 703002 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Trnava : Investigational Site Number 703001 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Slovenia
Ljubljana : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Many Locations : Updated
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Spain
Alicante : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Alicante : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Badalona : Hospital Germans Trias i Pujol
A Phase IIa Study of NT-KO-003 for Multiple Sclerosis
Barcelona : Hospital Clinic i Provincial
A Phase IIa Study of NT-KO-003 for Multiple Sclerosis
Barcelona : Hospital Vall d'Hebrón
A Phase IIa Study of NT-KO-003 for Multiple Sclerosis
View More »
Barcelona : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Barcelona : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Barcelona : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Barcelona : Investigational Site Number 724001 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Barcelona : Investigational Site Number 724002 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Barcelona : GSK Investigational Site Updated
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
Bilbao : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Bilbao : Investigational Site Number 724006 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Castellón : GSK Investigational Site Updated
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
Cordoba : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Córdoba : Investigational Site Number 724009 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Girona : Hospital Universitari Josep Trueta
A Phase IIa Study of NT-KO-003 for Multiple Sclerosis
Girona : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Girona : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Girona : Investigational Site Number 724003 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Girona : Research Site
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS
L´Hospitalet de Llobregat : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Madrid : Hospital Universitario La Paz
A Phase IIa Study of NT-KO-003 for Multiple Sclerosis
Madrid : Hospital Universitario Puerta del Hierro
A Phase IIa Study of NT-KO-003 for Multiple Sclerosis
Madrid : Hospital Clínico San Carlos
A Phase IIa Study of NT-KO-003 for Multiple Sclerosis
Madrid : Hospital Universitario La Princesa
A Phase IIa Study of NT-KO-003 for Multiple Sclerosis
Madrid : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Madrid : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Madrid : Investigational Site Number 724004 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Madrid : Investigational Site Number 724005 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Malaga : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Malaga : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Málaga : Hospital Regional Universitario Carlos Haya
A Phase IIa Study of NT-KO-003 for Multiple Sclerosis
Murcia : Investigational Site Number 724007 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Santiago de Compostela : Complexo Hospitalario Universitario de Santiago
A Phase IIa Study of NT-KO-003 for Multiple Sclerosis
Sevilla : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Sevilla : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Sevilla : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Sevilla : Investigational Site Number 724008 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Sevilla : GSK Investigational Site Updated
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
Valencia : Hospital Universitario La Fe
A Phase IIa Study of NT-KO-003 for Multiple Sclerosis
Sweden
Eskilstuna : Investigational Site Number 752002 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Göteborg : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Göteborg : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Göteborg : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Göteborg : Investigational Site Number 752004 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
View More »
Linköping : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Malmö : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Örebro : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Stockholm : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Stockholm : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Stockholm : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Stockholm : Investigational Site Number 752001 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Stockholm : Investigational Site Number 752003 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Umeå : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Umeå : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Switzerland
Basel : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Basel : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Bern : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Lausanne : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Lugano : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
View More »
Lugano : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Lugano : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
St. Gallen : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Zug : Biogen Idec International GmbH, Global Medical Affairs
TOP: IMA-06-02 Tysabri Observational Program
Zurich : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Syrian Arab Republic
Many Locations : Updated
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Taiwan
Many Locations : Updated
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Tunisia
Manouba : Investigational Site Number 788002 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Monastir : Investigational Site Number 788005 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Sfax : Investigational Site Number 788004 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Tunis : Investigational Site Number 788006 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Turkey
?stanbul : Investigational Site Number 8310 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Edirne : Investigational Site Number 8304 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Istanbul : Investigational Site Number 8309 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Istanbul : Investigational Site Number 8312 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Istanbul : Investigational Site Number 8308 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
View More »
Izmir : Investigational Site Number 8305 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Izmir : Investigational Site Number 8303 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Izmir : Investigational Site Number 8301 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Izmit : Investigational Site Number 8302 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Trabzon : Investigational Site Number 8314 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Ukraine
Chernihiv : Investigational Site Number 8507 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Chernivtsi : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Dnepropetrovsk : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Dnipropetrovsk : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Dnipropetrovsk : Investigational Site Number 8501 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
View More »
Donetsk : Investigational Site Number 8511 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Kharkiv : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Kharkiv : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Kharkiv : Investigational Site Number 8506 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Kharkov : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Kharkov : Investigational Site Number 8504 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Kiev : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Kiev : Investigational Site Number 8508 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Kyiv : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Kyviv : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Lutsk : Investigational Site Number 8512 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Lviv : Investigational Site Number 8505 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Odesa : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Odessa : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Poltava : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Poltava : Investigational Site Number 8510 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Vinnitsa : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Vinnytsya : Investigational Site Number 8503 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Zaporozhye : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Zaporozhye : Investigational Site Number 8502 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
United Kingdom
Birmingham : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Birmingham : Investigational Site Number 826008 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Brighton : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Brighton : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Bristol : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
View More »
Devon : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Edinburgh : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Leeds : Investigational Site Number 826005 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Liverpool : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Liverpool : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Liverpool : Investigational Site Number 826006 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Liverpool : Investigational Site Number 8709 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
London : GSK Investigational Site
[18F]PBR111 and Microglial Activation in Multiple Sclerosis
London : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
London : National Hospital for Neurology & Neurosurgery
ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis
London : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
London : Investigational Site Number 826003 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
London : University College of London, Institute of Neurology
Efficacy of Clean Intermittent Catheterization in MS Patients With Bladder Dysfunction
London : Imperial College NHS Trust
Patient Research Cohort: Rapidly Evolving Multiple Sclerosis
London : Investigational Site Number 8704 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
London : Investigational Site Number 8701 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Manchester : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Manchester : Morhosys Investigative Site
Phase Ib Study to Evaluate the Safety and Pharmacokinetics of MOR103, a Human Antibody to GM-CSF, in Patients With Multiple Sclerosis
Many Locations : Updated
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Many Locations : Updated
Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis
Merck KGaA Communication Center for recruiting locations : Please conatact the Updated New
The Impact of Disease Modifying Therapies (DMTs) and Associated Support Services on Patient Reported Experience Measures (PREMs) and Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Morriston : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
New Castle Upon Tyne : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Nottingham : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Nottingham : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Nottingham : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Nottingham : Investigational Site Number 8705 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Nottingham : Research Site
Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing Remitting Multiple Sclerosis
Plymouth : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Plymouth : Investigational Site Number 826004 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Plymouth : Investigational Site Number 8708 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Plymouth : Research Site
Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing Remitting Multiple Sclerosis
Salford : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Salford : Investigational Site Number 826001 Updated
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Salford : Investigational Site Number 8707 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Sheffield : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Sheffield : Royal Hallamshire Hospital
ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis
Sheffield : Research Site
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Sheffield : Royal Hallamshire Hospitals NHS Trust
Open-Label Study to Assess the Effect of Fampridine-PR on Quality of Life as Reported by Subjects With Multiple Sclerosis
Sheffield : Investigational Site Number 8702 Updated
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Stoke on Trent : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Swansea : Research Site
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Swansea : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
United States
DC : Research Site Updated
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Washington : Research Site
An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
Venezuela
Many Locations : Updated
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment